Obesity, MorbidFundoRingMGBNCT04834635
The FundoRingOAGB Versus Non-wrapping (Non-banded) Standard Method of Laparoscopic One Anastomosis Gastric Bypass
A study testing FundoRingOAGB and OAGB in people with Obesity, Morbid, run by The Society of Bariatric and Metabolic Surgeons of Kazakhstan at 1 site in Kazakhstan.
Trial summary
Currently, one anastomosis gastric bypass (OAGB) or mini-gastric bypass (MGB) is a common bariatric procedure for treating obesity. Weight gain after surgery is a big problem in bariatric practice. Therefore, adjustable bands and rings are used, for example, "FobiRing". Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Obesity, Morbid
- What is being tested?
- FundoRingOAGB and OAGB
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 1 siteKazakhstan
- Study dates
- 29 Mar 2021to 17 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- BMI from 30 to 50 kg / m2.
- The person is generally fit for anesthesia (ASA grading 1-2) and surgery.
- The person commits to the need for long-term follow-up.
Who cannot join
- BMI less than 30 kg / m2 and more than 50 kg / m2.
- Prosthetic (mesh) Hiatal herniorrhaphy or large hiatal hernia;
- Esophageal shortening
- Los Angeles Classification of Oesophagitis (LA grade) C or D reflux esophagitis
- History of surgery on the stomach or esophagus
- Less than 18 or more than 60 years of age
Show all 9Show fewer
- Not fit for bariatric surgery
- Psychiatric illness
- Patients unwilling or unable to provide informed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Total Wrapping of the Fundus of the Gastric Excluded Part (FundoRing) Versus Non- Wrapping (Non-banded) Standard Method of Laparoscopic One Anastomosis Gastric Bypass/Mini - Gastric Bypass: A Randomized Controlled Trial
Currently, one anastomosis gastric bypass (OAGB) or mini-gastric bypass (MGB) is a common bariatric procedure for treating obesity. Weight gain after surgery is a big problem in bariatric practice. Therefore, adjustable bands and rings are used, for example, "FobiRing". But foreign material can cause complications - the erosion of the stomach wall. For this reason, surgeons avoid the use of various mechanical devices on living tissues.
The greatest criticism is of the OAGB for the likelihood of biliary reflux. In case of reflux of bile into the esophagus after surgery, as a rule, a second operation is required with conversion OAGB to the Roux-en-Y method.
Read more
In addition, along with obesity, gastroesophageal reflux disease (GERD) are steadily increasing world weight and antireflux surgery must be performed simultaneously with bariatric surgery in obese patients. In these cases, most often in bariatric practice, hiatus cruroraphy is performed, and less often fundoplication using the fundus of the excluded part of the stomach.
We hypothesize that total fundoplication can not only treat GERD but also significant prevent the return of weight like after a banded gastric bypass and prevent postoperative bile reflux in the esophagus.
The aim study is to compare primary outcome as weight loss after total wrapping of the fundus of the gastric excluded part (FundoRing) and non - wrapping (non - banded) standard method of laparoscopic one anastomosis gastric bypass and measure secondary outcome: bile reflux in the esophagus and GERD symptoms.
Methods: Adult participants (n=1000) are randomly allocated to one of two groups:
Experimental surgical bariatric procedure in the first (A) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and suture cruroplasty if present hiatal hernia (FundoRingOAGB group); Active comparator surgical bariatric procedure in the second (B) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass and with only suture cruroplasty if present hiatal hernia (OAGB group).
Read the detailed description
One anastomosis Gastric Bypass/Mini Gastric Bypass (OAGB/MGB) is gaining popularity as a primary surgical treatment for morbid obesity.
The aim study is to compare primary outcome as weight loss after total wrapping of the fundus of the gastric excluded part (FundoRing) and non - wrapping (non - banded) standard method of laparoscopic one anastomosis gastric bypass and measure secondary outcome: bile reflux in the esophagus and GERD symptoms.
Methods: Adult participants (n=1000) are randomly allocated to one of two groups:
Experimental surgical bariatric procedure in the first (A) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and suture cruroplasty if present hiatal hernia (FundoRingOAGB group); Active comparator surgical bariatric procedure in the second (B) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass and with only suture cruroplasty if present hiatal hernia (OAGB group). All patients are then followed up 12, 24, 36 months after surgery where record the changing body mass index and and measure secondary outcome: bile reflux in the esophagus and GERD symptoms.
- Conditions
- Obesity, Morbid
- Being tested
- FundoRingOAGB, OAGB
- Keywords
- Obesity, Bariatric surgery, One anastomosis gastric bypass, FundoRingOAGB, Fundoplication
- Medical subject headings
- Obesity, Morbid, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FundoRingOAGBProcedure or surgery
laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia
OAGBProcedure or surgery
laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
| Study group | Role | What they receive |
|---|---|---|
| FundoRingOAGB group | Experimental | laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part (and suture cruroplasty if present hiatal hernia). Receives: Procedure: FundoRingOAGB |
| OAGB group | Active comparator | laparoscopic one anastomosis gastric bypass (and suture cruroplasty if present hiatal hernia). Receives: Procedure: OAGB |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of body mass index
The measure is assessing a change of body mass index (kg/m2) in groups . Weight (kg) and height (cm) will be combined with the report of measurement by body mass index (BMI) kg/m2.
Measured: Baseline, at 12, 24, 36, 60 months after surgery
Number of participants with bile reflux in esophagus
Endoscopic assessment of bile reflux in esophagus and 24-hour pH-impedance monitoring to detect number of postoperative esophageal bile reflux (non-acid reflux) in in each group
Measured: at 12, 24, 36 months after surgery
Number of participants with GERD symptoms
Change of GERD symptoms (use GERD Health-related Quality of Life (GERD-HRQL) Questionnaire) if present GERD or number of participants with postoperative de Novo GERD.
Scoring Scale 0 = No symptoms
- = Symptoms noticeable but not bothersome
- = Symptoms noticeable and bothersome but not every day
- = Symptoms bothersome every day
- = Symptoms affect daily activities
- = Symptoms are incapacitating - unable to do daily activities
Measured: Baseline, 12, 24, 36 months after surgery
Frequency of late (>30 day) postoperative complication in each groups
Namber participants with late postoperative complication ( dumping syndrome, marginal ulcer, food intolerance, protein malnutrition, anemia, thiamine deficiency)
Measured: >30 days, at 12, 24, 36 months after surgery
Chance of the components of Metabolic Syndrome (MetS) after surgery
Chance of level of HbA1c (<5,7%), level of HOMA-IR (<2.7) , < number participants with type 2 diabetes and arterial hypertension and chanqe of Lipid profile (Total Cholesterol: <200 mg/dL, LDL Cholesterol: <100 mg/dL (optimal), HDL Cholesterol: >60 mg/dL (desirable), Triglycerides: <150 mg/dL) at 1 and 3-year follow-up.
Measured: baseline, 1 and 3-year follow-up
Cases of recurrent weight gain (The percentage total weight loss (%TWL) lower than 35%)
Maintenance of a weight loss of 35% or more after weight loss surgery at 5 years was classified as superior weight loss (no significant weight regain). Patients with a weight loss of less than 35% at 60 months after surgery were classified as having weight regain (recurence). For comparison with earlier studies, the percentage of excess weight loss (%EWL) was also calculated for each time point using the following formula: (baseline weight - weight at follow-up)/(baseline weight - ideal body weight) × 100. Ideal body weight was set at a BMI of 25, resulting in the following formula: weight (kg) = 25 × height (m)².
Measured: 60 months after surgery
Secondary outcomes (2)
Oral glucose tolerance tests
A standard 3-hour oral glucose tolerance tests performs using 75 g glucose
Measured: Blood samples for glucose collects at 0, 15, 30, 60, 120, 150 and 180 minutes, while those for insulin collects at 0, 30, 60, 120 and 180 minutes
Sigstad score
Sigstad score for questionnaire of diagnostic the dumping syndrome. The Sigstad score is a diagnostic index for dumping syndrome, with a score >7 indicating a high probability of the condition, while a score < 4 suggests alternative diagnoses.
Key Elements of the Sigstad Scoring System:
- Thresholds: < or =3 (Negative), 4-7 (Doubtful), >7 (Positive for dumping).
- Key Symptoms Evaluated: Shock (+5), almost fainting/syncope (+4), desire to lie/sit down (+4), sweating/pallor (+4), palpitations (+2), nausea, and abdominal fullness.
Measured: 6, 12, 24, 36 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2021
- Study start29 Mar 2021
- Primary completion5 Apr 2024
- Study completion17 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Obesity, MorbidStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- The Society of Bariatric and Metabolic Surgeons of Kazakhstan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Oral Ospanov, Principal investigator, President of Society of Bariatric and Metabolic Surgeons of Kazakhstan" (SBMSK)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04834635
- Sponsor's protocol ID
- FundoRingOAGB
- Acronym
- FundoRingMGB
- Status last verified
- May 2026
- First submitted
- 4 Apr 2021
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ospanov O, Yeleuov G, Fursov A, Yelembayev B, Fursov R, Sergazin Z, Mustafin A. A laparoscopic one anastomosis gastric bypass with wrapping versus nonwrapping fundus of the excluded part of the stomach to treat obese patients (FundoRingOAGB trial): study protocol for a randomized controlled trial. Trials. 2022 Apr 7;23(1):264. doi: 10.1186/s13063-022-06252-6.
PubMed 35392958Ospanov O. The Surgical Technique of Primary Modified Fundoplication Using the Excluded Stomach with Simultaneous Gastric Bypass. Obes Surg. 2023 Apr;33(4):1311-1313. doi: 10.1007/s11695-023-06505-6. Epub 2023 Feb 17.
PubMed 36800158Ospanov O, Yeleuov G, Buchwald JN, Zharov N, Yelembayev B, Sultanov K. A Randomized Controlled Trial of Acid and Bile Reflux Esophagitis Prevention by Modified Fundoplication of the Excluded Stomach in One-Anastomosis Gastric Bypass: 1-Year Results of the FundoRing Trial. Obes Surg. 2023 Jul;33(7):1974-1983. doi: 10.1007/s11695-023-06618-y. Epub 2023 Apr 26.
PubMed 37099252Ospanov O, Yelembayev B, Buchwald JN, Sultanov K, Rakhmetov M, Duysenov G, Tuleuov B. Comparative endoscopic ultrasound assessment of the gastric pouch after FundoRing-OAGB and OAGB. BMC Surg. 2025 Dec 2;26(1):23. doi: 10.1186/s12893-025-03386-7.
PubMed 41331600Ospanov OB. The Gastric Bypass and Fundoplication in Bariatric Surgery: the Comments on Published Papers and Our Classification of Combination Procedures. Obes Surg. 2021 Oct;31(10):4643-4644. doi: 10.1007/s11695-021-05505-8. Epub 2021 Jun 1.
PubMed 34059995
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Total Wrapping of the Fundus of the Gastric Excluded Part (FundoRing) Versus Non- Wrapping (Non-banded) Standard Method of Laparoscopic One Anastomosis Gastric Bypass/Mini - Gastric Bypass: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04834635
- Acronym / sponsor ID
- FundoRingMGB / FundoRingOAGB
- Conditions
- Obesity, Morbid
- Keywords
- Obesity, Bariatric surgery, One anastomosis gastric bypass, FundoRingOAGB, Fundoplication
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- The Society of Bariatric and Metabolic Surgeons of KazakhstanUniversity, hospital or other
- Study start
- 29 Mar 2021 (actual)
- Primary completion
- 5 Apr 2024 (actual)
- Study completion
- 17 May 2026 (actual)
- First posted
- 8 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Currently, one anastomosis gastric bypass (OAGB) or mini-gastric bypass (MGB) is a common bariatric procedure for treating obesity. Weight gain after surgery is a big problem in bariatric practice. Therefore, adjustable bands and rings are used, for example, "FobiRing". But foreign material can cause complications - the erosion of the stomach wall. For this reason, surgeons avoid the use of various mechanical devices on living tissues.
The greatest criticism is of the OAGB for the likelihood of biliary reflux. In case of reflux of bile into the esophagus after surgery, as a rule, a second operation is required with conversion OAGB to the Roux-en-Y method.
In addition, along with obesity, gastroesophageal reflux disease (GERD) are steadily increasing world weight and antireflux surgery must be performed simultaneously with bariatric surgery in obese patients. In these cases, most often in bariatric practice, hiatus cruroraphy is performed, and less often fundoplication using the fundus of the excluded part of the stomach.
We hypothesize that total fundoplication can not only treat GERD but also significant prevent the return of weight like after a banded gastric bypass and prevent postoperative bile reflux in the esophagus.
The aim study is to compare primary outcome as weight loss after total wrapping of the fundus of the gastric excluded part (FundoRing) and non - wrapping (non - banded) standard method of laparoscopic one anastomosis gastric bypass and measure secondary outcome: bile reflux in the esophagus and GERD symptoms.
Methods: Adult participants (n=1000) are randomly allocated to one of two groups:
Experimental surgical bariatric procedure in the first (A) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and suture cruroplasty if present hiatal hernia (FundoRingOAGB group); Active comparator surgical bariatric procedure in the second (B) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass and with only suture cruroplasty if present hiatal hernia (OAGB group).
Detailed description
One anastomosis Gastric Bypass/Mini Gastric Bypass (OAGB/MGB) is gaining popularity as a primary surgical treatment for morbid obesity.
The aim study is to compare primary outcome as weight loss after total wrapping of the fundus of the gastric excluded part (FundoRing) and non - wrapping (non - banded) standard method of laparoscopic one anastomosis gastric bypass and measure secondary outcome: bile reflux in the esophagus and GERD symptoms.
Methods: Adult participants (n=1000) are randomly allocated to one of two groups:
Experimental surgical bariatric procedure in the first (A) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and suture cruroplasty if present hiatal hernia (FundoRingOAGB group); Active comparator surgical bariatric procedure in the second (B) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass and with only suture cruroplasty if present hiatal hernia (OAGB group). All patients are then followed up 12, 24, 36 months after surgery where record the changing body mass index and and measure secondary outcome: bile reflux in the esophagus and GERD symptoms.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| FundoRingOAGB group | Experimental | Procedure: FundoRingOAGBlaparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part (and suture cruroplasty if present hiatal hernia). |
| OAGB group | Active comparator | Procedure: OAGBlaparoscopic one anastomosis gastric bypass (and suture cruroplasty if present hiatal hernia). |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- BMI from 30 to 50 kg / m2.
- The person is generally fit for anesthesia (ASA grading 1-2) and surgery.
- The person commits to the need for long-term follow-up.
Key exclusion criteria (9 listed)
- BMI less than 30 kg / m2 and more than 50 kg / m2.
- Prosthetic (mesh) Hiatal herniorrhaphy or large hiatal hernia;
- Esophageal shortening
- Los Angeles Classification of Oesophagitis (LA grade) C or D reflux esophagitis
- History of surgery on the stomach or esophagus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FundoRingOAGBlaparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia | Procedure or surgery | FundoRingOAGB group |
| OAGBlaparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia | Procedure or surgery | OAGB group |
Primary outcome
Change of body mass index
Time frame: Baseline, at 12, 24, 36, 60 months after surgery
The measure is assessing a change of body mass index (kg/m2) in groups . Weight (kg) and height (cm) will be combined with the report of measurement by body mass index (BMI) kg/m2.
Number of participants with bile reflux in esophagus
Time frame: at 12, 24, 36 months after surgery
Endoscopic assessment of bile reflux in esophagus and 24-hour pH-impedance monitoring to detect number of postoperative esophageal bile reflux (non-acid reflux) in in each group
Number of participants with GERD symptoms
Time frame: Baseline, 12, 24, 36 months after surgery
Change of GERD symptoms (use GERD Health-related Quality of Life (GERD-HRQL) Questionnaire) if present GERD or number of participants with postoperative de Novo GERD. Scoring Scale 0 = No symptoms 1. = Symptoms noticeable but not bothersome 2. = Symptoms noticeable and bothersome but not every day 3. = Symptoms bothersome every day 4. = Symptoms affect daily activities 5. = Symptoms are incapacitating - unable to do daily activities
Frequency of late (>30 day) postoperative complication in each groups
Time frame: >30 days, at 12, 24, 36 months after surgery
Namber participants with late postoperative complication ( dumping syndrome, marginal ulcer, food intolerance, protein malnutrition, anemia, thiamine deficiency)
Chance of the components of Metabolic Syndrome (MetS) after surgery
Time frame: baseline, 1 and 3-year follow-up
Chance of level of HbA1c (<5,7%), level of HOMA-IR (<2.7) , < number participants with type 2 diabetes and arterial hypertension and chanqe of Lipid profile (Total Cholesterol: <200 mg/dL, LDL Cholesterol: <100 mg/dL (optimal), HDL Cholesterol: >60 mg/dL (desirable), Triglycerides: <150 mg/dL) at 1 and 3-year follow-up.
Cases of recurrent weight gain (The percentage total weight loss (%TWL) lower than 35%)
Time frame: 60 months after surgery
Maintenance of a weight loss of 35% or more after weight loss surgery at 5 years was classified as superior weight loss (no significant weight regain). Patients with a weight loss of less than 35% at 60 months after surgery were classified as having weight regain (recurence). For comparison with earlier studies, the percentage of excess weight loss (%EWL) was also calculated for each time point using the following formula: (baseline weight - weight at follow-up)/(baseline weight - ideal body weight) × 100. Ideal body weight was set at a BMI of 25, resulting in the following formula: weight (kg) = 25 × height (m)².
2 secondary outcomes
Oral glucose tolerance tests
Time frame: Blood samples for glucose collects at 0, 15, 30, 60, 120, 150 and 180 minutes, while those for insulin collects at 0, 30, 60, 120 and 180 minutes
Sigstad score
Time frame: 6, 12, 24, 36 months after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Results publication: PubMed 35392958Ospanov O, Yeleuov G, Fursov A, Yelembayev B, Fursov R, Sergazin Z, Mustafin A. A laparoscopic one anastomosis gastric bypass with wrapping versus nonwrapping fundus of the excluded part of the stomach to treat obese patients (FundoRingOAGB trial): study protocol for a randomized controlled trial. Trials. 2022 Apr 7;23(1):264. doi: 10.1186/s13063-022-06252-6.
- Results publication: PubMed 36800158Ospanov O. The Surgical Technique of Primary Modified Fundoplication Using the Excluded Stomach with Simultaneous Gastric Bypass. Obes Surg. 2023 Apr;33(4):1311-1313. doi: 10.1007/s11695-023-06505-6. Epub 2023 Feb 17.
- Results publication: PubMed 37099252Ospanov O, Yeleuov G, Buchwald JN, Zharov N, Yelembayev B, Sultanov K. A Randomized Controlled Trial of Acid and Bile Reflux Esophagitis Prevention by Modified Fundoplication of the Excluded Stomach in One-Anastomosis Gastric Bypass: 1-Year Results of the FundoRing Trial. Obes Surg. 2023 Jul;33(7):1974-1983. doi: 10.1007/s11695-023-06618-y. Epub 2023 Apr 26.
- Derived from this study: PubMed 41331600Ospanov O, Yelembayev B, Buchwald JN, Sultanov K, Rakhmetov M, Duysenov G, Tuleuov B. Comparative endoscopic ultrasound assessment of the gastric pouch after FundoRing-OAGB and OAGB. BMC Surg. 2025 Dec 2;26(1):23. doi: 10.1186/s12893-025-03386-7.
- Derived from this study: PubMed 34059995Ospanov OB. The Gastric Bypass and Fundoplication in Bariatric Surgery: the Comments on Published Papers and Our Classification of Combination Procedures. Obes Surg. 2021 Oct;31(10):4643-4644. doi: 10.1007/s11695-021-05505-8. Epub 2021 Jun 1.
- A laparoscopic one anastomosis gastric bypass with wrapping versus nonwrapping fundus of the excluded part of the stomach to treat obese patients (FundoRingOAGB trial): study protocol for a randomized controlled trialLink provided by the sponsor.
- The Surgical Technique of Primary Modified Fundoplication Using the Excluded Stomach with Simultaneous Gastric BypassLink provided by the sponsor.
- A Randomized Controlled Trial of Acid and Bile Reflux Esophagitis Prevention by Modified Fundoplication of the Excluded Stomach in One-Anastomosis Gastric Bypass: 1-Year Results of the FundoRing TrialLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Obesity, Morbid
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Not yet recruitingObservational study
Evaluating Metabolic Health in Individuals With Extreme Obesity
BMI>40
Enrolling by invitationObservational study
Bariatric Surgery Registry
Obesity, Morbid
Not yet recruitingObservational study
Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With Obesity
Obesity, Morbid, Postmenopause
Active, not recruiting
Mindfulness Based Eating Awareness Training for Bariatric Surgery Patients
Obesity, Morbid, Eating Disorder Symptom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Oral Ospanov principal investigator
President of Society of Bariatric and Metabolic Surgeons of Kazakhstan" (SBMSK)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing FundoRingOAGB and OAGB in people with Obesity, Morbid, run by The Society of Bariatric and Metabolic Surgeons of Kazakhstan at 1 site in Kazakhstan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of body mass index (time frame: Baseline, at 12, 24, 36, 60 months after surgery). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04834635, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.